Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSNASDAQ:BFRINASDAQ:ENSCNASDAQ:MBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.12+280.7%$0.04$0.00▼$0.78$1.35M1.186,351 shs1,730 shsBFRIBiofrontera$0.66+1.4%$0.70$0.54▼$2.22$6.23M0.29935,163 shs149,655 shsENSCEnsysce Biosciences$2.07-3.3%$2.29$1.62▼$14.67$4.91M0.97944,772 shs45,742 shsMBIOMustang Bio$1.17-7.9%$1.24$1.01▼$65.00$5.12M2.24327,425 shs92,272 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals+280.70%+263.44%+301.00%+301.00%-56.25%BFRIBiofrontera+1.38%+9.83%-5.72%-28.80%-36.02%ENSCEnsysce Biosciences-3.27%-13.03%-10.39%-46.79%-74.25%MBIOMustang Bio-7.87%-5.65%+4.46%-17.02%-84.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABFRIBiofrontera2.5011 of 5 stars3.53.00.00.02.40.01.3ENSCEnsysce Biosciences0.3694 of 5 stars0.04.00.00.02.10.00.0MBIOMustang Bio0.3805 of 5 stars0.03.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/ABFRIBiofrontera 3.00Buy$2.75317.30% UpsideENSCEnsysce Biosciences 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADXS, BFRI, MBIO, and ENSC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025BFRIBiofronteraBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $2.75(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M1.58N/AN/A($2.06) per share-0.06BFRIBiofrontera$38.00M0.16N/AN/A$3.16 per share0.21ENSCEnsysce Biosciences$2.23M2.20N/AN/A($3.10) per share-0.67MBIOMustang BioN/AN/AN/AN/A$0.67 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/ABFRIBiofrontera-$20.13M-$2.26N/AN/AN/A-36.31%-565.73%-96.64%8/13/2025 (Estimated)ENSCEnsysce Biosciences-$10.61M-$6.54N/AN/AN/A-179.26%-292.81%-158.83%8/13/2025 (Estimated)MBIOMustang Bio-$51.60M-$78.00N/AN/AN/AN/AN/A-172.89%8/12/2025 (Estimated)Latest ADXS, BFRI, MBIO, and ENSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BFRIBiofrontera-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/A5/13/2025Q1 2025ENSCEnsysce Biosciences-$3.02-$1.39+$1.63-$1.39$0.65 million$1.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/ABFRIBiofronteraN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/ABFRIBiofronteraN/A1.530.94ENSCEnsysce BiosciencesN/A3.243.24MBIOMustang BioN/A0.400.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%BFRIBiofrontera10.08%ENSCEnsysce Biosciences5.63%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%BFRIBiofrontera1.20%ENSCEnsysce Biosciences7.90%MBIOMustang Bio0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableBFRIBiofrontera709.45 million7.73 millionNo DataENSCEnsysce Biosciences102.37 million1.20 millionNot OptionableMBIOMustang Bio1004.38 million952,000Not OptionableADXS, BFRI, MBIO, and ENSC HeadlinesRecent News About These CompaniesMustang Bio’s first-of-a-kind CAR-T starts trialsMay 1, 2025 | pharmaphorum.comMustang Bio meets Nasdaq’s equity listing requirementsMarch 8, 2025 | investing.comMustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy AdvancementsMarch 8, 2025 | nasdaq.comMustang Bio regains compliance with Nasdaq requirementMarch 5, 2025 | markets.businessinsider.comMustang Bio, Inc. Regains Compliance with Nasdaq Capital Market Listing RequirementsMarch 5, 2025 | quiverquant.comMustang Bio Regains Compliance with Nasdaq Capital Market RequirementMarch 5, 2025 | globenewswire.comBRIEF—Mustang Bio sells assets; focuses on MB-109, MB-108 and MB-101March 3, 2025 | thepharmaletter.comMustang Bio exits Worcester facility, sells assets to AbbVieMarch 1, 2025 | uk.investing.comMustang Bio closes Worcester facility, moves HQ to Waltham after reverse stock splitFebruary 28, 2025 | wbjournal.comMustang Bio Ends Manufacturing Facility Lease Hoping to Save, Plans Brain Tumor Cell Therapy TrialFebruary 28, 2025 | precisionmedicineonline.comMustang Bio, Inc.: Mustang Bio Announces Sale of Fixed Assets and Exit of FacilityFebruary 28, 2025 | finanznachrichten.deMustang Bio to Exit Lease of Worcester, Mass. Manufacturing FacilityFebruary 27, 2025 | marketwatch.comMustang Bio exits lease for Massachusetts facility, divests equipmentFebruary 27, 2025 | markets.businessinsider.comMustang Bio stock plunges 29% on lease termination newsFebruary 27, 2025 | msn.comMustang Bio Announces Sale of Fixed Assets and Exit of FacilityFebruary 27, 2025 | globenewswire.comMustang Bio sells assets and ends lease with AbbVieFebruary 13, 2025 | msn.comMustang Bio stock plunges to 52-week low of $2.6 amid sharp declineFebruary 13, 2025 | msn.comMustang Bio regains compliance with NasdaqFebruary 11, 2025 | markets.businessinsider.comMustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public OfferingFebruary 11, 2025 | quiverquant.comMustang Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 11, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXS, BFRI, MBIO, and ENSC Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.12 +0.09 (+280.70%) As of 06/13/2025 11:30 AM EasternAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Biofrontera NASDAQ:BFRI$0.66 +0.01 (+1.38%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.65 -0.01 (-1.82%) As of 06/13/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Ensysce Biosciences NASDAQ:ENSC$2.07 -0.07 (-3.27%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.Mustang Bio NASDAQ:MBIO$1.17 -0.10 (-7.87%) Closing price 06/13/2025 03:57 PM EasternExtended Trading$1.17 0.00 (0.00%) As of 06/13/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
